13 research outputs found
Computational Approaches for Structure Based Drug Design and Protein Structure-Function Prediction
This dissertation thesis consists of a series of chapters that are interwoven by solving interesting biological problems, employing various computational methodologies. These techniques provide meaningful physical insights to promote the scientific fields of interest. Focus of chapter 1 concerns, the importance of computational tools like docking studies in advancing structure based drug design processes. This chapter also addresses the prime concerns like scoring functions, sampling algorithms and flexible docking studies that hamper the docking successes. Information about the different kinds of flexible dockings in terms of accuracy, time limitations and success studies are presented. Later the importance of Induced fit docking studies was explained in comparison to traditional MD simulations to predict the absolute binding modes.
Chapter 2 and 3 focuses on understanding, how sickle cell disease progresses through the production of sickled hemoglobin and its effects on sickle cell patients. And how, hydroxyurea, the only FDA approved treatment of sickle cell disease acts to subside sickle cell effects. It is believed the primary mechanism of action is associated with the pharmacological elevation of nitric oxide in the blood, however, the exact details of this mechanism is still unclear. HU interacts with oxy and deoxyHb resulting in slow NO production rates. However, this did not correlate with the observed increase of NO concentrations in patients undergoing HU therapy. The discrepancy can be attributed to the interaction of HU competing with other heme based enzymes such as catalase and peroxidases. In these two chapters, we investigate the atomic level details of this process using a combination of flexible-ligand / flexible-receptor virtual screening (i.e. induced fit docking, IFD) coupled with energetic analysis that decomposes interaction energies at the atomic level. Using these tools we were able to elucidate the previously unknown substrate binding modes of a series of hydroxyurea analogs to human hemoglobin, catalase and the concomitant structural changes of the enzymes. Our results are consistent with kinetic and EPR measurements of hydroxyurea-hemoglobin reactions and a full mechanism is proposed that offers new insights into possibly improving substrate binding and/or reactivity.
Finally in chapter 4, we have developed a 3D bioactive structure of O6-alkylguanine-DNA alkyltransferase (AGT), a DNA repair protein using Monte Carlo conformational search process. It is known that AGT prevents DNA damage, mutations and apoptosis arising from alkylated guanines. Various Benzyl guanine analouges of O6- methylguanine were tested for activity as potential inhibitors. The nature and position of the substitutions methyl and aminomethyl profoundly affected their activity. Molecular modeling of their interactions with alkyltransferase provided a molecular explanation for these results. The square of the correlation coefficient (R2 ) obtained between E-model scores (obtained from GLIDE XP/QPLD docking calculations) vs log(ED)values via a linear regression analysis was 0.96. The models indicate that the ortho-substitution causes a steric clash interfering with binding, whereas the meta-aminomethyl substitution allows an interaction of the amino group to generate an additional hydrogen bond with the protein. Using this model for virtually screening studies resulted in identification of seven lead compounds with novel scaffolds from National Cancer Institute Diversity Set2
How Does Catalase Release Nitric Oxide? A Computational Structure–Activity Relationship Study
Hydroxyurea (HU) is the only FDA approved medication for treating sickle cell disease in adults. The primary mechanism of action is pharmacological elevation of nitric oxide (NO) levels which induces propagation of fetal hemoglobin. HU is known to undergo redox reactions with heme based enzymes like hemoglobin and catalase to produce NO. However, specific details about the HU based NO release remain unknown. Experimental studies indicate that interaction of HU with human catalase compound I produces NO. Presently, we combine flexible receptor–flexible substrate induced fit docking (IFD) with energy decomposition analyses to examine the atomic level details of a possible key step in the clinical conversion of HU to NO. Substrate binding modes of nine HU analogs with catalase compound I were investigated to determine the essential properties necessary for effective NO release. Three major binding orientations were found that provide insight into the possible reaction mechanisms for producing NO. Further results show that anion/radical intermediates produced as part of these mechanisms would be stabilized by hydrogen bonding interactions from distal residues His75, Asn148, Gln168, and oxoferryl-heme. These details will ideally contribute to both a clearer mechanistic picture and provide insights for future structure based drug design efforts
Unlocking the Binding and Reaction Mechanism of Hydroxyurea Substrates as Biological Nitric Oxide Donors
Hydroxyurea is the only FDA approved treatment of sickle cell disease. It is believed that the primary mechanism of action is associated with the pharmacological elevation of nitric oxide in the blood; however, the exact details of this are still unclear. In the current work, we investigate the atomic level details of this process using a combination of flexible-ligand/flexible-receptor virtual screening coupled with energetic analysis that decomposes interaction energies. Utilizing these methods, we were able to elucidate the previously unknown substrate binding modes of a series of hydroxyurea analogs to hemoglobin and the concomitant structural changes of the enzyme. We identify a backbone carbonyl that forms a hydrogen bond with bound substrates. Our results are consistent with kinetic and electron paramagnetic resonance (EPR) measurements of hydroxyurea–hemoglobin reactions, and a full mechanism is proposed that offers new insights into possibly improving substrate binding and/or reactivity
Unlocking the Binding and Reaction Mechanism of Hydroxyurea Substrates as Biological Nitric Oxide Donors
Hydroxyurea is the only FDA approved treatment of sickle
cell disease. It is believed that the primary mechanism of action
is associated with the pharmacological elevation of nitric oxide in
the blood; however, the exact details of this are still unclear. In
the current work, we investigate the atomic level details of this
process using a combination of flexible-ligand/flexible-receptor virtual
screening coupled with energetic analysis that decomposes interaction
energies. Utilizing these methods, we were able to elucidate the previously
unknown substrate binding modes of a series of hydroxyurea analogs
to hemoglobin and the concomitant structural changes of the enzyme.
We identify a backbone carbonyl that forms a hydrogen bond with bound
substrates. Our results are consistent with kinetic and electron paramagnetic resonance (EPR) measurements of hydroxyurea–hemoglobin reactions, and a full
mechanism is proposed that offers new insights into possibly improving
substrate binding and/or reactivity
How Does Catalase Release Nitric Oxide? A Computational Structure–Activity Relationship Study
Hydroxyurea (HU) is the only FDA
approved medication for treating sickle cell disease in adults. The
primary mechanism of action is pharmacological elevation of nitric
oxide (NO) levels which induces propagation of fetal hemoglobin. HU
is known to undergo redox reactions with heme based enzymes like hemoglobin
and catalase to produce NO. However, specific details about the HU
based NO release remain unknown. Experimental studies indicate that
interaction of HU with human catalase compound I produces NO. Presently,
we combine flexible receptor–flexible substrate induced fit
docking (IFD) with energy decomposition analyses to examine the atomic
level details of a possible key step in the clinical conversion of
HU to NO. Substrate binding modes of nine HU analogs with catalase
compound I were investigated to determine the essential properties
necessary for effective NO release. Three major binding orientations
were found that provide insight into the possible reaction mechanisms
for producing NO. Further results show that anion/radical intermediates
produced as part of these mechanisms would be stabilized by hydrogen
bonding interactions from distal residues His75, Asn148, Gln168, and
oxoferryl-heme. These details will ideally contribute to both a clearer
mechanistic picture and provide insights for future structure based
drug design efforts
Thiamin Diphosphate Activation in 1-Deoxy-d-xylulose 5-Phosphate Synthase: Insights into the Mechanism and Underlying Intermolecular Interactions
1-Deoxy-d-xylulose 5-phosphate synthase (DXS) is a thiamin diphosphate (TDP) dependent enzyme that marks the beginning of the methylerythritol 4-phosphate isoprenoid biosynthesis pathway. The mechanism of action for DXS is still poorly understood and begins with the formation of a thiazolium ylide. This TDP activation step is thought to proceed through an intramolecular deprotonation by the 4′-aminopyrimidine ring of TDP; however, this step would occur only after an initial deprotonation of its own 4′-amino group. The mechanism of the initial deprotonation has been hypothesized, by analogy to transketolases, to occur via a histidine or an active site water molecule. Results from hybrid quantum mechanical/molecular mechanical (QM/MM) reaction path calculations reveal an ∼10 kcal/mol difference in transition state energies, favoring a water mediated mechanism over direct deprotonation by histidine. This difference was determined to be largely governed by electrostatic changes induced by conformational variations in the active site. Additionally, mutagenesis studies reveal DXS to be an evolutionarily resilient enzyme. Particularly, we hypothesize that residues H82 and H304 may act in a compensatory fashion if the other is lost due to mutation. Further, nucleus-independent chemical shifts (NICSs) and aromatic stabilization energy (ASE) calculations suggest that reduction in TDP aromaticity also serves as a factor for regulating ylide formation and controlling reactivity
Identification and Characterization of Noncovalent Interactions That Drive Binding and Specificity in DD-Peptidases and β‑Lactamases
Bacterial
resistance to standard (i.e., β-lactam-based) antibiotics
has become a global pandemic. Simultaneously, research into the underlying
causes of resistance has slowed substantially, although its importance
is universally recognized. Key to unraveling critical details is characterization
of the noncovalent interactions that govern binding and specificity
(DD-peptidases, antibiotic targets, versus β-lactamases, the
evolutionarily
derived enzymes that play a major role in resistance) and ultimately
resistance as a whole. Herein, we describe a detailed investigation
that elicits new chemical insights into these underlying intermolecular
interactions. Benzylpenicillin and a novel β-lactam peptidomimetic
complexed to the Stremptomyces R61
peptidase are examined using an arsenal of computational techniques:
MD simulations, QM/MM calculations, charge perturbation analysis,
QM/MM orbital analysis, bioinformatics, flexible receptor/flexible
ligand docking, and computational ADME predictions. Several key molecular
level interactions are identified that not only shed light onto fundamental
resistance mechanisms, but also offer explanations for observed specificity.
Specifically, an extended π–π network is elucidated
that suggests antibacterial resistance has evolved, in part, due to
stabilizing aromatic interactions. Additionally, interactions between
the protein and peptidomimetic substrate are identified and characterized.
Of particular interest is a water-mediated salt bridge between Asp217
and the positively charged N-terminus of the peptidomimetic, revealing
an interaction that may significantly contribute to β-lactam
specificity. Finally, interaction information is used to suggest modifications
to current β-lactam compounds that should both improve binding
and specificity in DD-peptidases and their physiochemical properties
Thiamin Diphosphate Activation in 1‑Deoxy‑d‑xylulose 5‑Phosphate Synthase: Insights into the Mechanism and Underlying Intermolecular Interactions
1-Deoxy-d-xylulose 5-phosphate synthase (DXS) is a thiamin
diphosphate (TDP) dependent enzyme that marks the beginning of the
methylerythritol 4-phosphate isoprenoid biosynthesis pathway. The
mechanism of action for DXS is still poorly understood and begins
with the formation of a thiazolium ylide. This TDP activation step
is thought to proceed through an intramolecular deprotonation by the
4′-aminopyrimidine ring of TDP; however, this step would occur
only after an initial deprotonation of its own 4′-amino group.
The mechanism of the initial deprotonation has been hypothesized,
by analogy to transketolases, to occur via a histidine or an active
site water molecule. Results from hybrid quantum mechanical/molecular
mechanical (QM/MM) reaction path calculations reveal an ∼10
kcal/mol difference in transition state energies, favoring a water
mediated mechanism over direct deprotonation by histidine. This difference
was determined to be largely governed by electrostatic changes induced
by conformational variations in the active site. Additionally, mutagenesis
studies reveal DXS to be an evolutionarily resilient enzyme. Particularly,
we hypothesize that residues H82 and H304 may act in a compensatory
fashion if the other is lost due to mutation. Further, nucleus-independent
chemical shifts (NICSs) and aromatic stabilization energy (ASE) calculations
suggest that reduction in TDP aromaticity also serves as a factor
for regulating ylide formation and controlling reactivity
Modeling Boronic Acid Based Flourescent Saccharide Sensors: Computational Investigation of d-Fructose Binding to Dimethylaminomethylphenylboronic Acid (DMPBA)
Designing organic saccharide sensors for use in aqueous solution is a non-trivial endeavor. Incorporation of hydrogen bonding groups on a sensor’s receptor unit to target saccharides is an obvious strategy, but not one that is likely to ensure analyte-receptor interactions over analyte-solvent or receptor-solvent interactions. Phenylboronic acids are known to reversibly and covalently bind saccharides (diols in general) with highly selective affinity in aqueous solution. Therefore, recent work has sought to design such sensors and understand their mechanism for allowing fluorescence with bound saccharides. In past work, binding orientations of several saccharides were determined to dimethylaminomethylphenylboronic acid (DMPBA) receptors with an anthracene fluorophore, however the binding orientation of D-fructose to such a sensor could not be determined. In this work, we investigate the potential binding modes by generating 20 possible bidentate and six possible tridentate modes between fructose and DMPBA, a simplified receptor model. Gas phase and implicit solvent geometry optimizations, with a myriad functional/basis set pairs, were carried out to identify the lowest energy bidentate and tridentate binding modes of D-fructose to DMPBA. An interesting hydrogen transfer was observed during selected bidentate gas phase optimizations, this transfer suggests a strong sharing of the hydrogen atom between the boronate hydroxyl and amine nitrogen